Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment

Phase 2CBL-514CBL-0201WRtirzepatidePositive

AI Analysis

Summary

Caliway received FDA IND clearance for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide, and obtained IRB approval to initiate enrollment in the pivotal Phase 3 trial SUPREME-01.

Clinical Trial Data

Phase

2/3

Outcome Details

IND clearance for CBL-0201WR Phase 2 trial and IRB approval for pivotal Phase 3 trial SUPREME-01 initiated

Importance:6/10

Sentiment:

0.70

FDA clearanceIND approvalPhase 2Phase 3combination therapyclinical trial

Read the original article

Published by PR Newswire Biotech on August 26, 2026 1:24 AM

Read Original